Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 11/30/2016 |
| Start Date: | January 2013 |
| End Date: | March 2017 |
Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer
A prostate cancer diagnosis starts a list of events that often leads to fast-moving
treatment, thought by many to result in vast over-treatment of this disease. So, discovery
of different diagnostic methods that allow clinicians to identify slow-growing from
potentially fast-growing disease prior to or at the time of prostate biopsy could result in
early and suitable treatment for men at greatest risk, while greatly decreasing the number
of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and
patient worry, for those with more slow-growing disease.
treatment, thought by many to result in vast over-treatment of this disease. So, discovery
of different diagnostic methods that allow clinicians to identify slow-growing from
potentially fast-growing disease prior to or at the time of prostate biopsy could result in
early and suitable treatment for men at greatest risk, while greatly decreasing the number
of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and
patient worry, for those with more slow-growing disease.
Inclusion Criteria:
- Prostate cancer diagnosis prior to treatment
- Age 21 years or older
- Signed informed subject consent
- Prostatectomy as planned prostate cancer treatment
Exclusion Criteria:
- Men who do not choose prostatectomy
- Men who have undergone any neoadjuvant therapy
- Men who have cardiac pacemakers or other implanted electronic devices
- Men who have any surgically implanted metal
- Men who have had any surgical procedure that precludes placement of endorectal probe
- Indication of dementia or memory issues listed on problem list
- Men who indicate exposure to ocular metal fragments; confirmed by positive ocular
x-ray
- Men who are taking newly-prescribed (within 6 months of enrollment) lipid control
medications
We found this trial at
2
sites
Portland, Oregon 97239
Principal Investigator: Jonathan Q Purnell, MD
Click here to add this to my saved trials
Click here to add this to my saved trials